What Clair Health’s Continuous Hormone Tracking Wearable Is
Clair Health’s hormone tracking wearable is a non-invasive, wrist-worn device that continuously infers key female hormones from physiological signals, turning endocrine patterns into a daily vital sign for women’s health, performance, and longevity. Built by two Stanford graduates, the jewelry-inspired device models activity across estrogen, progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) without blood draws or urine tests. Instead, it combines 10 biosensors and more than 130 proprietary biomarkers to power machine learning models that estimate hormonal changes over time. Co-founder Jenny Duan argues that most wearables monitor heart rate variability, sleep, steps and breathing, yet overlook hormones that shape those signals for women. By adding an endocrine “data layer” on top of existing metrics, Clair aims to explain fluctuations that current devices can only observe in isolation, positioning continuous hormone monitoring as the next logical step after sleep tracking and continuous glucose monitoring.
The $11.6M Seed Round and What It Signals
Clair Health has raised USD 11.6 million (approx. RM54.0 million) in funding, in a round led by Khosla Ventures with participation from a16z speedrun and other investors. According to Longevity.Technology, this capital is intended to support the company’s November 2026 launch and ongoing research into continuous hormone monitoring. The funding comes as consumer wearables reach mainstream adoption; Rock Health reports that 57% of Americans now own a wearable or connected device, making new buyers harder to find. Investors see Clair’s appeal not only in the device, but in the potential to build a large, longitudinal hormonal dataset that underpins personalized women’s health wearables. As a16z speedrun partner Emily Bennett notes, women’s health has been an underserved category where users “have been left to guess about what’s truly going on below the surface,” and data-driven hormone insights may finally change that.
Designing a Jewelry-Inspired Non-Invasive Wearable Technology
Clair’s decision to design its hormone tracking wearable as jewelry is more than aesthetic; it is a strategic move to lower barriers to adoption for women wary of medicalized hardware. The wrist-worn device resembles a bracelet rather than a clinical monitor, helping it fit into daily life and social settings without drawing attention. Under the polished exterior, the device uses a network of biosensors to gather continuous physiological data, then applies machine learning to infer hormone levels over time. This non-invasive wearable technology echoes how other consumer devices estimate heart rate variability or sleep phases without directly sampling blood. By making continuous hormone monitoring look and feel like an accessory, Clair positions its product alongside mainstream women’s health wearables rather than niche medical tools, targeting users interested in fertility, athletic performance, recovery, perimenopause and general well-being who might avoid more intrusive testing.
Rewriting the Map of Female Physiology
One of Clair’s most provocative claims is that continuous hormone monitoring reveals a far richer picture of female physiology than traditional four-phase menstrual cycle models. Co-founder and CTO Abhinav Agarwal reports that beta data suggest the ovary may move through nine distinct physiological stages per cycle, a fine-grained pattern that episodic hormone tests have struggled to capture. Some of these sub-phases appear in scientific literature, but Claire’s continuous, non-invasive measurements make them visible in everyday life. This shift from snapshots to trajectories mirrors how continuous glucose monitoring changed metabolic care and how biological age clocks reframed aging as a moving target. If validated, these nine sub-phases could reshape textbooks, clinical guidelines and how women interpret their own symptoms, from mood shifts and sleep changes to exercise recovery and perimenopausal transitions, making the hormone tracking wearable a tool for discovery as much as for daily tracking.
From Fertility to Preventive Care: The Future of Women’s Health Wearables
Clair Health’s funding and early traction—25,000 people on the waitlist and its initial 5,000-unit run sold out six months ahead of release—show rising demand for women’s health wearables that go beyond period logging and ovulation prediction. By layering continuous hormone monitoring onto existing metrics, the device aims to support fertility timing, detect hormonal conditions like PCOS, and guide training or recovery for athletes. Longer term, Clair and its investors see hormones as foundational healthspan signals, particularly in under-measured transitions such as perimenopause. Non-invasive, continuous monitoring could flag subtle hormonal imbalances earlier than sporadic lab testing, opening the door to more personalized treatment plans and preventive interventions. For clinicians and researchers, the aggregated endocrine data could become a rich resource to study patterns across populations, while for users, the hormone tracking wearable reframes hormones as a daily, interpretable aspect of self-care.
